Revenue Breakdown
Composition ()
No data
Revenue Streams
Bio-Techne Corp (TECH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 80.8% of total sales, equivalent to $231.60M. Other significant revenue streams include Service and Instruments. Understanding this composition is critical for investors evaluating how TECH navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Bio-Techne Corp maintains a gross margin of 66.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.84%, while the net margin is 13.33%. These profitability ratios, combined with a Return on Equity (ROE) of 3.80%, provide a clear picture of how effectively TECH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TECH competes directly with industry leaders such as BMRN and RNA. With a market capitalization of $9.90B, it holds a significant position in the sector. When comparing efficiency, TECH's gross margin of 66.37% stands against BMRN's 81.33% and RNA's 100.00%. Such benchmarking helps identify whether Bio-Techne Corp is trading at a premium or discount relative to its financial performance.
